Filter articles using the following links

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

BIO 2020, San Diego (CA), US – Digital

2020 ARVO Annual Meeting, Baltimore (MD), US – cancelled

ASGCT 23rd Annual Meeting, Boston (MA), USA – Virtual Format

GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors